EyePoint Pharmaceuticals

company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery

PSDV Nasdaq ISIN US30233G2093 SEC CIK 1314102 LEI 549300QE1RU34T50MR69
Follow EyePoint Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $756K −21.7% vs same quarter last year
Net income −$95.6M −60.1% vs same quarter last year
EPS, diluted −$1.07 −25.9% vs same quarter last year
Operating cash flow −$86.8M −46.3% vs same quarter last year
Revenue by quarter
$11.6M
$24.5M
$5.3M
$966K
$620K
$696K
$507K
$756K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$31.4M−$232M
FY24$43.3M−$130.9M
FY23$46M−$70.8M
FY22$41.4M−$102.3M
FY21$36.9M−$58.4M
FY20$34.4M−$45.4M
FY19$20.4M−$56.8M
FY18$3M−$53.2M
FY17$7.5M−$18.5M
FY16$1.6M−$21.5M
FY15$26.6M$6.3M
FY14$3.5M−$13.4M
FY13$2.1M−$11.9M
FY12$3.5M−$24.8M
FY11$5M−$8.6M
MarginsShare of revenue
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−776%−739.4%
FY24−337.1%−302.4%
FY23−163.1%−153.8%
FY22−240.6%−247%
FY21−149.6%−158.1%
FY20−108.3%−131.8%
FY19−235%−278.9%
FY18−887.3%−1795.7%
FY17−246.4%−245.2%
FY16−1344.1%−1330.1%
FY1524.2%23.9%
FY14−388.4%−384.5%
FY13−561.4%−555.3%
FY12−715%−704.3%
FY11−201.5%−173.8%
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$243.4M
FY24−$130.3M
FY23−$1.6M
FY22−$67.2M
FY21−$50.3M
FY20−$14.8M
FY19−$56.9M
FY18−$22M
FY17−$20.6M
FY16−$16.4M
FY15$10.1M
FY14−$10.9M
FY13−$8.8M
FY12−$9.4M
FY11−$3.3M
Net margin vs the sectorMedian of Technology companies filing with the SEC
  • EyePoint Pharmaceuticals
  • Technology median
−2000%−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearEyePoint PharmaceuticalsTechnology median
FY25−739.4%−2.3%
FY24−302.4%−5%
FY23−153.8%−6.7%
FY22−247%−4.4%
FY21−158.1%−1.7%
FY20−131.8%−3%
FY19−278.9%0%
FY18−1795.7%0.8%
FY17−245.2%2%
FY16−1330.1%2.3%
FY1523.9%3.1%
FY14−384.5%2.9%
FY13−555.3%3.9%
FY12−704.3%3.9%
FY11−173.8%5.7%